This page contains a Flash digital edition of a book.
Neurodegenerative Disease Parkinson’s Disease 2011;134:11–23. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77.


Heckers S, Geula C, Mesulam M, Cholinergic innervation of the human thalamus: Dual origin and differential nuclear distribution, J Comp Neurol, 1992;325:68–82.


Winn P, How best to consider the structure and function of the pedunculopontine tegmental nucleus: evidence from animal studies, J Neurol Sci, 2006;248:234–50.


Lavoie B, Parent A, Pedunculopontine nucleus in the squirrel monkey: projections to the basal ganglia as revealed by anterograde tract-tracing methods, J Comp Neurol, 1994;344:210–31.


Zweig RM, Jankel WR, Hedreen JC, et al., The pedunculopontine nucleus in Parkinson’s disease, Ann Neurol, 1989;26:41–6.


Gai WP, Halliday GM, Blumbergs PC, et al., Substance P- containing neurons in the mesopontine tegmentum are severely affected in Parkinson’s disease, Brain, 1991;114:2253–67.


Karachi C, Grabli D, Bernard FA, et al., Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease, J Clin Invest, 2010;120:2745–54.


Jenkinson N, Nandi D, Miall RC, et al., Pedunculopontine nucleus stimulation improves akinesia in a Parkinsonian monkey, Neuroreport, 2004;15:2621–4.


Garcia-Rill E, Houser CR, Skinner RD, et al., Locomotion-inducing sites in the vicinity of the pedunculopontine nucleus, Brain Res Bull, 1987;18:731–8.


Hasselmo ME, Sarter M, Modes and models of forebrain cholinergic neuromodulation of cognition, Neuropsychopharmacology, 2011;36:52–73.


Bohnen NI, Kaufer DI, Ivanco LS, et al., Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study, Arch Neurol, 2003;60:1745–8.


78. 79. 80.


Shimada H, Hirano S, Shinotoh H, et al., Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET, Neurology, 2009;73:273–8.


Bohnen NI, Albin RL, The cholinergic system and Parkinson disease, Behav Brain Res, 2011;221:564–73.


Spuz CA, Paolone G, Briscoe S, et al., Deficits in attentional control of balance, mobility, and complex movements in a rat model of early state, multisystem Parkinson disease, Society for Neuroscience, Washington DC, November 2011, Abstract 244.02.


81. 82. 83.


Bohnen NI, Muller ML, Koeppe RA, et al., History of falls in Parkinson disease is associated with reduced cholinergic activity, Neurology, 2009;73:1670–6.


Alves G, Larsen JP, Emre M, et al., Changes in motor subtype and risk for incident dementia in Parkinson’s disease, Mov Disord, 2006;21:1123–30.


Taylor JP, Rowan EN, Lett D, et al., Poor attentional function predicts cognitive decline in patients with non-demented Parkinson’s disease independent of motor phenotype, J Neurol Neurosurg Psychiatry, 2008;79:1318–23.


84. 85. 86.


Grimbergen YA, Langston JW, Roos RA, Bloem BR, Postural instability in Parkinson’s disease: the adrenergic hypothesis and the locus coeruleus, Expert Rev Neurother, 2009;9:279–90.


Moore RY, Bloom FE, Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems, Annu Rev Neurosci, 1979;2:113–68.


Zarow C, Lyness SA, Mortimer JA, Chui HC, Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases, Arch Neurol, 2003;60:337–41.


87. 88. 89.


Gunning-Dixon FM, Raz N, The cognitive correlates of white matter abnormalities in normal aging: A quantitative review, Neuropsychology, 2000;14:224–32.


Pantoni L, Garcia JH, Pathogenesis of leukoaraiosis, Stroke, 1997;28:652–9.


Longstreth WT, Jr, Manolio TA, Arnold A, et al., Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study, Stroke, 1996;27:1274–82.


90. 91.


Baezner H, Blahak C, Poggesi A, et al., Association of gait and balance disorders with age-related white matter changes: the LADIS study, Neurology, 2008;70:935–42.


Murray ME, Senjem ML, Petersen RC, et al., Functional impact of white matter hyperintensities in cognitively normal elderly


96. 97. 98. 99. 92. 93. 94. 95. subjects, Arch Neurol, 2010;67:1379–85.


Bohnen NI, Muller ML, Zarzhevsky N, et al., Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson’s disease, Brain, 2011;134:2358–65.


Schneider JA, Bennett DA, Where vascular meets neurodegenerative disease, Stroke, 2010;41:S144–6.


Chung KA, Lobb BM, Nutt JG, Horak F, Cholinergic augmentation in frequently fallings subjects with Parkinson’s disease, Mov Disord, 2009;24(Suppl. 1):S259.


Ceravolo R, Volterrani D, Frosini D, et al., Brain perfusion effects of cholinesterase inhibitors in Parkinson’s disease with dementia, J Neural Transm, 2006;113:1787–90.


Ahlskog JE, Think before you leap: donepezil reduces falls?, Neurology, 2010;75:1226–7.


Montero-Odasso M, Wells J, Borrie M, Can cognitive enhancers reduce the risk of falls in people with dementia? An open-label study with controls, J Am Geriatr Soc, 2009;57:359–60.


Sarter M, Parikh V, Howe WM, nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms, Biochem Pharmacol, 2009;78:658–67.


Pollak L, Dobronevsky Y, Prohorov T, et al., Low dose methylphenidate improves freezing in advanced Parkinson’s disease during off-state, J Neural Transm Suppl, 2007:145–8.


100. Devos D, Krystkowiak P, Clement F, et al., Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson’s disease, J Neurol Neurosurg Psychiatry, 2007;78:470–5.


101. Auriel E, Hausdorff JM, Herman T, et al., Effects of methylphenidate on cognitive function and gait in patients with Parkinson’s disease: a pilot study, Clin Neuropharmacol, 2006;29:15–7.


102. Nutt JG, Carter JH, Carlson NE, Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial, Arch Neurol, 2007;64:319–23.


103. Auriel E, Hausdorff JM, Giladi N, Methylphenidate for the treatment of Parkinson disease and other neurological disorders, Clin Neuropharmacol, 2009;32:75–81.


104. Espay AJ, Dwivedi AK, Payne M, et al., Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial, Neurology, 2011;76:1256–62.


105. Jankovic J, Atomoxetine for freezing of gait in Parkinson disease, J Neurol Sci, 2009;284:177–8.


106. Benabid AL, Pollak P, Gervason C, et al., Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus, Lancet, 1991;337:403–6.


107. Deuschl G, Bain P, Deep brain stimulation for tremor [correction of trauma]: patient selection and evaluation, Mov Disord, 2002;17(Suppl. 3):S102–11.


108. Pahwa R, Lyons KE, Wilkinson SB, et al., Long-term evaluation of deep brain stimulation of the thalamus, J Neurosurg, 2006;104:506–12.


109. Bakker M, Esselink RA, Munneke M, et al., Effects of stereotactic neurosurgery on postural instability and gait in Parkinson’s disease, Mov Disord, 2004;19:1092–9.


110. Weaver FM, Follett K, Stern M, et al., Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial, JAMA, 2009;301:63–73.


111. Follett KA, Weaver FM, Stern M, et al., Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease, N Engl J Med, 2010;362:2077–91.


112. Krack P, Batir A, Van Blercom N, et al., Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease, N Engl J Med, 2003;349:1925–34.


113. Liang GS, Chou KL, Baltuch GH, et al., Long-term outcomes of bilateral subthalamic nucleus stimulation in patients with advanced Parkinson’s disease, Stereotact Funct Neurosurg, 2006;84:221–7.


114. Ostergaard K, Aa Sunde N, Evolution of Parkinson’s disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus, Mov Disord, 2006;21:624–31.


115. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al., Bilateral deep brain stimulation in Parkinson’s disease: a multicentre study with 4 years follow-up, Brain, 2005;128:2240–9.


116. Schupbach WM, Chastan N, Welter ML, et al., Stimulation of the


subthalamic nucleus in Parkinson’s disease: a 5 year follow up, J Neurol Neurosurg Psychiatry, 2005;76:1640–4.


117. Castrioto A, Lozano AM, Poon YY, et al., Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation, Arch Neurol, 2011;68:1550–6.


118. St George RJ, Nutt JG, Burchiel KJ, Horak FB, A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD, Neurology, 2010;75:1292–9.


119. Moreau C, Defebvre L, Destee A, et al., STN-DBS frequency effects on freezing of gait in advanced Parkinson disease, Neurology, 2008;71:80–4.


120. Brozova H, Barnaure I, Alterman RL, Tagliati M, STN-DBS frequency effects on freezing of gait in advanced Parkinson disease, Neurology, 2009;72:770; author reply 770–1.


121. Brudzynski SM, Houghton PE, Brownlee RD, Mogenson GJ, Involvement of neuronal cell bodies of the mesencephalic locomotor region in the initiation of locomotor activity of freely behaving rats, Brain Res Bull, 1986;16:377–81.


122. Milner KL, Mogenson GJ, Electrical and chemical activation of the mesencephalic and subthalamic locomotor regions in freely moving rats, Brain Res, 1988;452:273–85.


123.


Plaha P, Gill SS, Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson’s disease, Neuroreport, 2005;16:1883–7.


124. Bacskai BJ, Frosch MP, Freeman SH, et al., Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report, Arch Neurol, 2007;64:431–4.


125. Ferraye MU, Debu B, Fraix V, et al., Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson’s disease, Brain, 2010;133:205–14.


126. Moro E, Hamani C, Poon YY, et al., Unilateral pedunculopontine stimulation improves falls in Parkinson’s disease, Brain, 2010;133:215–24.


127. Ostrem JL, Christine CW, Glass GA, et al., Pedunculopontine nucleus deep brain stimulation in a patient with primary progressive freezing gait disorder, Stereotact Funct Neurosurg, 2010;88:51–5.


128. Zrinzo L, Zrinzo LV, Surgical anatomy of the pedunculopontine and peripeduncular nuclei, Br J Neurosurg, 2008;22(Suppl. 1):S19–24.


129. Khan S, Mooney L, Plaha P, et al., Outcomes from stimulation of the caudal zona incerta and pedunculopontine nucleus in patients with Parkinson’s disease, Br J Neurosurg, 2011;25:273–80.


130. Morris ME, Martin CL, Schenkman ML, Striding out with Parkinson disease: evidence-based physical therapy for gait disorders, Phys Ther, 2010;90:280–8.


131. Kwakkel G, de Goede CJ, van Wegen EE, Impact of physical therapy for Parkinson’s disease: a critical review of the literature, Parkinsonism Relat Disord, 2007;13(Suppl. 3):S478–87.


132. Goodwin VA, Richards SH, Taylor RS, et al., The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis, Mov Disord, 2008;23:631–40.


133. Dibble LE, Addison O, Papa E, The effects of exercise on balance in persons with Parkinson’s disease: a systematic review across the disability spectrum, J Neurol Phys Ther, 2009;33:14–26.


134. Allen NE, Sherrington C, Paul SS, Canning CG, Balance and falls in Parkinson’s disease: A meta-analysis of the effect of exercise and motor training, Mov Disord, 2011;26:1605–15.


135. Cakit BD, Saracoglu M, Genc H, et al., The effects of incremental speed-dependent treadmill training on postural instability and fear of falling in Parkinson’s disease, Clin Rehabil, 2007;21:698–705.


136.


Mehrholz J, Friis R, Kugler J, et al., Treadmill training for patients with Parkinson’s disease, Cochrane Database Syst Rev, 2010;(1):CD007830.


137. Hackney ME, Earhart GM, Tai Chi improves balance and mobility in people with Parkinson disease, Gait Posture, 2008;28:456–60.


138. Ridgel AL, Kim CH, Fickes EJ, et al., Changes in executive function after acute bouts of passive cycling in Parkinson’s disease, J Aging Phys Act, 2011;19:87–98.


108


US NEUROLOGY


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108